Use of benzimidazole quinolinones for treating cancer
CA 2501932 C · Owner: Novartis Vaccines And Diagnostics, Inc. · Inventors: Zhu, Shuguang; Machajewski, Timothy D.; Harwood, Eric
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods of treating cancer using 4-amino-5-fluoro-3-6-(4-methylpiperazin-1yl)-1H-benzimidazol-2-ylquinolin-2(1H)-one are provided. In particular the , methods are effective for the treatment of solid tumors or leukemias including prostate, colorectal, breast multiple myeloma, pancreatic, small , cell carcinoma acute myelogenous leukemia, chronic myelogenous leukemia or , myelo-proliferative disease. Further provided are methods of measuring the amount of 4-amino-5-fluoro-3-6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2ylquinolin-2(1H)-one and determining a metabolic profile therefore.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 12, 2003 and granted March 11, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 12, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 12, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.